Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28319922 | 0.96 | DPP4 (0.61) | DPP4PDGFRBPDGFRAMAPTGAA | |
| SCHEMBL29409636 | 0.91 | DPP4 (0.53) | DPP4PDGFRBPDGFRAMAPTGAA | |
| SCHEMBL22589588 | 0.91 | DPP4 (0.53) | DPP4PDGFRBPDGFRAMAPTGAA | |
| SCHEMBL4651297 | 0.90 | DPP4 (0.52) | DPP4MAPTGAATHRBNPSR1 | |
| SCHEMBL2725474 | 0.90 | MAPT (0.60) | DPP4MAPTGAATHRBNPSR1 | |
| SCHEMBL23575550 | 0.90 | MAPT (0.55) | DPP4PDGFRBPDGFRAMAPTGAA | |
| Buquinolate SCHEMBL30589264 | 0.87 | DPP4 (0.45) | DPP4MAPTGAATHRBNPSR1 | |
| Buquinolate SCHEMBL1404252 | 0.87 | DPP4 (0.45) | DPP4MAPTGAATHRBNPSR1 | |
| SCHEMBL2921747 | 0.85 | DPP4 (0.58) | DPP4PDGFRBPDGFRAMAPTGAA | |
| SCHEMBL30449564 | 0.85 | DPP4 (0.58) | DPP4PDGFRBPDGFRAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005121125-A1 | ETHER-LINKED HETEROARYL COMPOUNDS | PFIZER INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-1263503-B1 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | WYETH CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1549297-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | Wyeth Holdings Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040122048-A1 | Stabilized pharmaceutical composition containing basic excipients | WYETH HOLDINGS CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2004032909-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | WYETH HOLDINGS CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-0973746-B1 | SUBSTITUTED 3-CYANO QUINOLINES | WYETH CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| CN-1121391-C | Substituted 3-cyano quinolines | AMERICAN CYANAMID CO (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| CN-1259125-A | Substituted 3-cyanoquinolines | AMERICAN CYANAMID CO (US) | 2000-07-05 | — | — | CN | disclosed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
| US-4079058-A | Process of performing cyclization reactions using benzyl or pyridylamino malonic acid derivatives | DYNAMIT NOBEL AG (DT) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122048-A1 | Stabilized pharmaceutical composition containing basic excipients | F7, H1-10, F12 | DPP4 3651/4885PDGFRB 3775/4885PDGFRA 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.